ProQR Therapeutics « Terug naar discussie overzicht

quote:

holenbeer schreef op 27 juni 2019 16:53:

Evoke gaat lekker. Hebben meeting met FDA aangevraagd.
Kunnen hopelijk weer naar 3, nu 0,66

quote:

4finance schreef op 27 juni 2019 20:51:

[...]

Wat is het onderliggende verhaal van deze toko dat het weer naar $3 "kan" ?

quote:

joel12 schreef op 27 juni 2019 20:20:

QUESTION you guys.. suddenly thought of something. could PROQR receive conditional approval pending excellent phase1/2 results to be presented this fall? could the company in fact become conditionally commercial as soon as this year?
just a thought that came to mind.. i mean, who will not give it if it makes people see again?

quote:

joel12 schreef op 28 juni 2019 09:31:

dont be so sure Tom. here IS my logic
1) first the drug received already fast-track-designation
2) which provides Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met

the fact that the drug is fast tracked, it means that it fulfills a serious condition and if phase 1/2 which final data will be coming in fall, I believe Proqr could ask for early conditional approval .. which the Phase 3 could solidify or the FDA could revert the approval.

not to forget that SAREPTA received approval for testing its drug in ONLY 12 kids.

1 more item that came in last JMP .. the CEO said the FDA is ready to get approval even if ALLL patients are to develop cataract. that means that even that is not a barrier for Proqr to get approval and as for the efficacy the CEO mentioned 1 person which started to see after only 1 injection .. 15 years after being completely blind.

I think now more than ever that if the results are good in fall, Proqr will get conditional approval, the FDA will not wait another year for many to loose their sight. no safety issue and if it shows as good or better efficacy Proqr will be commercial. thats my thought. EOM

quote:

nb schreef op 28 juni 2019 19:07:

Remember to be back in september

quote:

RW1963 schreef op 28 juni 2019 19:27:

[...]

Als de koers dan laag staat en ik nog geld over heb ;-)

Blijf ProQR sowieso volgen, want ben er helemaal niet blij mee dat ik er vanaf ben. Maar die daling duurt gewoon te lang en stopt maar niet.

quote:

Tom3 schreef op 28 juni 2019 19:13:

[...]

Why we have touched the 9$ mark you think? Remember that the last shares/ secondary offering were sold for $ 15+. A lot of trust has evaporated.

quote:

Guy-vdk schreef op 28 juni 2019 20:27:

Na eindelijk nog eens een dagje groen gisteren is de daling weer begonnen,er komt maar geen eind aan..Ik wacht rustig af tot het najaar om weer te kopen.Wie weet staan ze dan weer 3 dollar.

quote:

joel12 schreef op 28 juni 2019 20:14:

no no Silence.. again this company is an RNAi company not RNA editing.

there is a strong group in Germany which focuses on RNA editing and is doing similar things as Proqr with Axiomer. although ophtamology is its current focus, in order to become a self sustained enterprise, the Axiomer is the most valuable asset it has which could revolutionize medicine and really give CRISPr a fight.

I envision that Proqr may embark in setting up a subsidiary that focuses on RNA editing. the group in Germany could be a venue.